Taking medicine that is supposed to balance your body out but ends up being stronger than it should be is a little unsettling. That’s what Vitruvias Therapeutics Inc. was facing when it decided to recall some of its Thyroid Tablets, USP 30 mg. It wasn’t because the product was bad or tainted, but because tests showed it might be stronger than what was listed on the label. The medical term for this is “superpotent.”
The recalled lot, which had the number 504950 and an expiration date of September 30, 2026, was sent all over the United States from January 31, 2025, to September 30, 2025. About 1,955 of the 3,655 units that Vitruvias Therapeutics sent to its direct accounts were actually sold. By drug company standards, that’s not a huge number, but for the people holding those bottles—who probably have a long-term thyroid condition that affects their energy, weight, mood, and heart rate—the news is very different.
In the field of pharmacology, thyroid medicines are in a unique place. There isn’t always a big difference between the right dose and too much, and the body usually picks up on an imbalance pretty quickly. The product from Vitruvias Therapeutics is a natural mixture made from pig thyroid glands. It contains both levothyroxine and liothyronine and is used to treat hypothyroidism, a condition in which the thyroid gland doesn’t make enough hormone on its own. If the treatment goes too far, it can lead to hyperthyroidism, which is an overactive thyroid that has its own problems.
The company made these risks very clear: losing weight, being unable to handle heat, feeling tired, jittery, having weak muscles, having high blood pressure, chest pain, a fast heart rate, and problems with the heart’s rhythm. A short-term change in hormones might be uncomfortable for most healthy adults, but it won’t hurt them in the long run. But the worry grows a lot when you think about the people who are most at risk: elderly patients, pregnant women, and babies. Too much thyroid hormone has been linked to serious heart problems in older people. Overtreatment during pregnancy can lead to early delivery and babies that are too small for their parents. For babies, it might get in the way of their normal growth and development. These are not just theoretical worries. Because of them, the recall language has a lot of weight.
It is important to note that Vitruvias Therapeutics said it had not heard of any bad effects happening with this lot as of the time the recall was announced. It is hard to say for sure if that means there is real safety or just a reporting gap. Thyroid symptoms are usually spread out. For example, feeling tired or nervous could have a dozen other causes before someone thinks to blame their medication lot number.
Right now, what’s important for patients is the advice that the company has given them: don’t stop taking the medicine without first talking to a doctor or nurse. There are risks that come with stopping thyroid treatment all of a sudden. The goal is a smooth transition to a new prescription, not a sudden stop. Vitruvias Therapeutics is telling wholesalers to stop distributing the product and is making plans to destroy any remaining recalled stock.
This recall doesn’t exist by itself either. Major Pharmaceuticals voluntarily recalled levothyroxine sodium tablets earlier in 2025 after the FDA found that those pills did not deliver as much hormone as they were supposed to. The FDA gave that recall a Class II designation, which means there could be temporary bad effects on health. It affected a number of dosage strengths and package types. Two recalls of thyroid medications in the same year, for different reasons related to their effectiveness, make people wonder about the quality control processes in the category as a whole. It’s still not clear if this is a sign of a larger problem in the industry or just two separate failures that happened in the same year.
People who think they may have the recalled lot can find it by looking at the lot number 504950 or the National Drug Code number 69680-166-00. To ask a question, you can email Vitruvias Therapeutics at safety@vitruvias.com or call them at (256) 239-9373, Monday through Friday, 9 a.m. to 5 p.m. Central Time. Through its MedWatch program, people can also tell the FDA directly about bad effects.
Right now, the most helpful thing for someone with hypothyroidism is to quickly look at that pill bottle and call their doctor if the lot number works.
